IL181450A0 - Modulators of hepatocyte growth factor activator - Google Patents

Modulators of hepatocyte growth factor activator

Info

Publication number
IL181450A0
IL181450A0 IL181450A IL18145007A IL181450A0 IL 181450 A0 IL181450 A0 IL 181450A0 IL 181450 A IL181450 A IL 181450A IL 18145007 A IL18145007 A IL 18145007A IL 181450 A0 IL181450 A0 IL 181450A0
Authority
IL
Israel
Prior art keywords
modulators
growth factor
hepatocyte growth
factor activator
activator
Prior art date
Application number
IL181450A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL181450A0 publication Critical patent/IL181450A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL181450A 2004-10-04 2007-02-20 Modulators of hepatocyte growth factor activator IL181450A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61565704P 2004-10-04 2004-10-04
PCT/US2005/036300 WO2006042173A2 (en) 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator

Publications (1)

Publication Number Publication Date
IL181450A0 true IL181450A0 (en) 2007-07-04

Family

ID=36148972

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181450A IL181450A0 (en) 2004-10-04 2007-02-20 Modulators of hepatocyte growth factor activator

Country Status (15)

Country Link
US (4) US20060147451A1 (enExample)
EP (1) EP1809673B1 (enExample)
JP (2) JP4937127B2 (enExample)
KR (1) KR101252306B1 (enExample)
CN (1) CN101035810B (enExample)
AU (1) AU2005294146B2 (enExample)
BR (1) BRPI0515670A (enExample)
CA (1) CA2577598C (enExample)
ES (1) ES2398528T3 (enExample)
IL (1) IL181450A0 (enExample)
NO (1) NO20072302L (enExample)
NZ (1) NZ553327A (enExample)
RU (1) RU2418004C2 (enExample)
WO (1) WO2006042173A2 (enExample)
ZA (1) ZA200701789B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4937127B2 (ja) 2004-10-04 2012-05-23 ジェネンテック， インコーポレイテッド 肝細胞成長因子活性化物質のモジュレータ
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
EP2441472B1 (en) * 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
EP2125896A2 (en) * 2007-02-09 2009-12-02 Genetech, Inc. Anti-robo4 antibodies and uses therefor
EP4083072A1 (en) 2008-10-06 2022-11-02 Minerva Biotechnologies Corporation Muc1* antibodies
CA2771817A1 (en) * 2009-10-19 2011-04-28 Genentech, Inc. Modulators of hepatocyte growth factor activator
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
JP5814925B2 (ja) 2009-10-22 2015-11-17 ジェネンテック， インコーポレイテッド 抗ヘプシン抗体及びその使用方法
KR20130133205A (ko) 2010-11-10 2013-12-06 제넨테크, 인크. 신경계 질환 면역요법을 위한 방법 및 조성물
CN107250158B (zh) 2014-11-19 2022-03-25 基因泰克公司 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
EP3845565A3 (en) 2014-11-19 2021-09-08 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CN119095872A (zh) * 2022-03-07 2024-12-06 安立玺荣生医(香港)有限公司 抗cd36抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
CA2102463A1 (en) * 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US7045602B2 (en) * 2000-12-05 2006-05-16 Mitsubishi Chemical Corporation Specific antibody directed to active hepatocyte growth factor activator and method for using the same
JP4090236B2 (ja) * 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
JP4937127B2 (ja) 2004-10-04 2012-05-23 ジェネンテック， インコーポレイテッド 肝細胞成長因子活性化物質のモジュレータ

Also Published As

Publication number Publication date
AU2005294146B2 (en) 2011-09-15
US20060147451A1 (en) 2006-07-06
CN101035810B (zh) 2011-04-06
WO2006042173A3 (en) 2006-08-17
BRPI0515670A (pt) 2008-07-29
HK1105006A1 (en) 2008-02-01
EP1809673B1 (en) 2012-11-28
JP4937127B2 (ja) 2012-05-23
ES2398528T3 (es) 2013-03-19
RU2418004C2 (ru) 2011-05-10
WO2006042173A2 (en) 2006-04-20
US20130217862A1 (en) 2013-08-22
US20110098449A1 (en) 2011-04-28
JP2012025752A (ja) 2012-02-09
US8399629B2 (en) 2013-03-19
KR101252306B1 (ko) 2013-04-08
KR20070102470A (ko) 2007-10-18
JP5554298B2 (ja) 2014-07-23
US20090047291A1 (en) 2009-02-19
RU2007116806A (ru) 2008-11-10
EP1809673A2 (en) 2007-07-25
US7825221B2 (en) 2010-11-02
ZA200701789B (en) 2008-11-26
NO20072302L (no) 2007-06-28
CA2577598C (en) 2016-09-20
AU2005294146A1 (en) 2006-04-20
CN101035810A (zh) 2007-09-12
US8969528B2 (en) 2015-03-03
CA2577598A1 (en) 2006-04-20
JP2008515918A (ja) 2008-05-15
NZ553327A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
IL181450A0 (en) Modulators of hepatocyte growth factor activator
SI1636190T1 (sl) Stabilni kristal 4-oksokinolinske spojine
IL178564A0 (en) Improved modulators of coagulation factors
PT1786472E (pt) Modulação anti-sentido de expressão de apolipoproteína
IL210693A0 (en) Transcription factor modulating compounds and methods of use thereof
IL176958A0 (en) Compounds and methods of use
EP1773826A4 (en) MODULATORS OF C-MET AND THEIR METHOD OF USE
EP1751124A4 (en) RAF MODULATORS AND METHODS OF USE
IL189976A0 (en) Methods of modulating neurotrophin-mediated activity
PT1802579E (pt) Derivados da 3-arilaminopiridina
IL219655A0 (en) Hepatocyte growth factor binding proteins and methods of producing the same
ZA200508562B (en) Controlled manipulation of characters
IL179917A0 (en) Methods and compositions for modulating hepatocyte growth factor activation
EP1817277A4 (en) PHENYL DERIVATIVES AND METHOD OF USE
ZA200705561B (en) Stabilisation of radiopharmaceutical precursors
EP1597366A4 (en) MODULATION OF THE EXPRESSION OF THE INSULINARY GROWTH FACTOR I-RECEPTOR
SI1682537T1 (sl) Modulatorji celularne adhezije
IL179199A0 (en) Modulation of wrn-mediated telomere-initiated cell signaling
IL177647A0 (en) Use of enzyme
IL177106A0 (en) Oxydecahydronaphthalene modulators of hm74
ZA200608490B (en) Method of modulating vascularization
GB0510501D0 (en) Display of operational instructions
IL190408A0 (en) Hepatocyte growth factor receptor splice variants and methods of using same
PL114847U1 (en) Magnetic activator
PL114848U1 (en) Magnetic activator